American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 28, Issue 6 , Pages 375-378 , November 2007

RAD inhibition of sarcoma growth: implications for laryngeal transplantation

  • Philip Daniel Knott, MD

      Affiliations

    • Head and Neck Institute, The Cleveland Clinic Foundation, Cleveland, OH, USA
    • Corresponding Author InformationCorresponding author. Head and Neck Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Tel.: +1 216 444 6686; fax: +1 216 445-9409.
    • ,
  • Hidemasa Tamai, MD

      Affiliations

    • Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland, OH, USA
    • ,
  • Marshall Strome, MD, MS

      Affiliations

    • Head and Neck Institute, The Cleveland Clinic Foundation, Cleveland, OH, USA
    • ,
  • Fredrick Van Lente, PhD

      Affiliations

    • Department of Pathology and Laboratory Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA
    • ,
  • Suyu Shu, PhD

      Affiliations

    • Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland, OH, USA

Received 3 November 2006

References 

  1. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl. 1998;147–158
  2. Sedrani R, Cottens S, Kallen J, et al. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc. 1998;30:2192–2194
  3. Kahan BD, Kaplan B, Lorber MI, et al. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation. 2001;71(10):1400–1406
  4. Schuurman HJ, Schuler W, Ringers J, et al. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc. 1998;30:2198–2199
  5. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation. 2002;73:920–925
  6. Kovarik JM, Eisen H, Dorent R, et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant. 2003;22:1117–1125
  7. Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de novo renal transplant patients. Transplantation. 2003;75:2082–2085
  8. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847–858
  9. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36–42
  10. Farb A, John M, Acampado E, et al. Oral everolimus inhibits in-stent neointimal growth. Circulation. 2002;106:2379–2384
  11. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 1996;56:3895–3897
  12. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 1995;60:264–270
  13. Rohde J, Heitman J, Cardenas ME. The TOR kinases link nutrient sensing to cell growth. J Biol Chem. 2001;276(13):9583–9586
  14. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs. 2002;3(2):295–304
  15. Matsumoto Y, Hof A, Baumlin Y, et al. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E–deficient mice. Transplantation. 2003;76:1166–1170
  16. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003;75(10):1710–1717
  17. Adams G. Malignant tumors of the larynx and hypopharynx. In:  Cummings CW,  Fredrickson JM,  Harker LA, et al. editor. Otolaryngology head and neck surgery. 3rd ed. Philadelphia (PA): Mosby; 1998;p. 2130–2175
  18. Strome M. Human laryngeal transplantation: considerations and implications. Microsurgery. 2000;20:372–374

☆ This study was performed in accordance with the PHS Policy on Humane Care and Use of Laboratory Animals, the NIH Guide for the Care and Use of Laboratory Animals, and the Animal Welfare Act (7 USC et seq); the animal use protocol was approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic Foundation.

PII: S0196-0709(06)00287-0

doi: 10.1016/j.amjoto.2006.11.003

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 28, Issue 6 , Pages 375-378 , November 2007

Article Tools

* Image Usage & Resolution